BioLineRx Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles about it in the 4Search index. Click a dot on the chart for the event and the news of that day.
Key statistics
Against its peers
Compare in full ›| BLRX.TA | SNGX | BIVI | ATORX.ST | ABVC | ANIX | |
|---|---|---|---|---|---|---|
| Market cap | 29.87M | 5.14M | 8.58M | 28.54M | 23.37M | 84.82M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | — | -0.9 | -1.4 | -0.1 | -2.0 | -7.9 |
| Price/book | 2.0 | 0.8 | 1.1 | 0.2 | 1.7 | 5.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −47.37% | −82.98% | −29.73% | −98.80% | −67.29% | −40.09% |
| Today | 0.00% | −8.29% | −12.07% | −5.88% | −1.56% | −6.15% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All BLRX.TA news ›BioLineRx and Hemispherian Present Phase 1/2a Clinical Study and Pre-Clinical Updates, Including Brain PK/PD Data, at SNO 2026
News provided by BioLineRx Ltd.; Hemispherian AS - Fourth cohort initiated in ongoing Phase 1/2a study of GLIX1; remaining cohorts to include patients in window-of-opportunity setting - - GLIX1 demonstrated robust, dose-dependent antitumor…
BioLineRx (NASDAQ:BLRX) versus Nurix Therapeutics (NASDAQ:NRIX) Head-To-Head Comparison
Posted by Danessa Lincoln on Nov 11th, 2026 Share on Twitter Share on Facebook Share on LinkedIn Share on Stocktwits BioLineRx (NASDAQ:BLRX – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Fr
Contrasting BioLineRx (NASDAQ:BLRX) and Mirum Pharmaceuticals (NASDAQ:MIRM)
Posted by Sarita Garza on Nov 9th, 2026 Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) and BioLineRx (NASDAQ:BLRX – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two…
Reviewing BioLineRx (NASDAQ:BLRX) and Vertex Pharmaceuticals (NASDAQ:VRTX)
Posted by Danessa Lincoln on Oct 30th, 2026 BioLineRx (NASDAQ:BLRX – Get Free Report) and Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two…
HAX1 review highlights context-dependent roles in cancer progression
A 2026 review finds that the molecular scaffold HAX1 supports tumor growth, invasion, hypoxic adaptation and treatment resistance while showing promise as a prognostic biomarker and selective therapeutic target. Article Title: HAX1 in…
Transcript : BioLineRx Ltd., Q1 2026 Earnings Call, May 27, 2026
Presentation Operator MessageOperator Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx First Quarter 2026 Financial Results Conference. [Operator Instructions] I would now... Transcript : BioLineRx Ltd., Q1 2026…
BioLineRx Ltd. And Hemispherian AS Highlight New Data On GLIX1 At The American Society Of Clinical Oncology Annual Meeting
BioLineRx Ltd. and Hemispherian AS announced that two abstracts featuring GLIX1 will be published at the American Society of Clinical Oncology 2026 Annual Meeting, which is being held May 29-June 2,...
BioLineRx Ltd.: Relative Strength Chart - Stock TEL AVIV STOCK EXCHANGE
Compare BioLineRx Ltd. with the company of your choice via a Relative Strength chart. Real-time BLRX price, TEL AVIV STOCK EXCHANGE stock exchange Relative Strength Chart BioLineRx Ltd. Biotechnology & Medical Research All financial news…
BioLineRx Ltd.: Total Return chart (Dividends reinvested) - TEL AVIV STOCK EXCHANGE stock market
See the history of BioLineRx Ltd., with dividends reinvested. (Total Return chart) BLRX Stock market Total Return chart BioLineRx Ltd. Biotechnology & Medical Research All financial news and data tailored to specific country editions
BioLineRx Ltd. And Hemispherian AS Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect In Glioblastoma
BioLineRx Ltd. and Hemispherian AS announced highly encouraging new preclinical data that further support the recently initiated Phase 1/2a clinical trial evaluating GLIX1 for the treatment of... and Hemispherian AS announced highly…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- marketscreener.com5
- themarketsdaily.com3
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.